Pharmacokinetics, Placental and Breast Milk Transfer of Antiretroviral Drugs in Pregnant and Lactating Women Living with HIV

E.M.      Hodel; C.      Marzolini; C.       Waitt; N.      Rakhmanina
Abstract

Background: Remarkable progress has been achieved in the identification of HIV infection in pregnant women and in the prevention of vertical HIV transmission through maternal antiretroviral treatment (ART) and neonatal antiretroviral drug (ARV) prophylaxis in the last two decades. Millions of women globally are receiving combination ART throughout pregnancy and breastfeeding, periods associated with significant biological and physiological changes affecting the pharmacokinetics (PK) and pharmacodynamics (PD) of ARVs. The objective of this review was to summarize currently available knowledge on the PK of ARVs during pregnancy and transport of maternal ARVs through the placenta and into the breast milk. We also summarized main safety considerations for in utero and breast milk ARVs exposures in infants.
Methods: We conducted a review of the pharmacological profiles of ARVs in pregnancy and during breastfeeding obtained from published clinical studies. Selected maternal PK studies used a relatively rich sampling approach at each ante- and postnatal sampling time point. For placental and breast milk transport of ARVs, we selected the studies that provided ratios of maternal to the cord (M:C) plasma and breast milk to maternal plasma (M:P) concentrations, respectively.
Results: We provide an overview of the physiological changes during pregnancy and their effect on the PK parameters of ARVs by drug class in pregnancy, which were gathered from 45 published studies. The PK changes during pregnancy affect the dosing of several protease inhibitors during pregnancy and limit the use of several ARVs, including three single tablet regimens with integrase inhibitors or protease inhibitors co-formulated with cobicistat due to suboptimal exposures. We further analysed the currently available data on the mechanism of the transport of ARVs from maternal plasma across the placenta and into the breast milk and summarized the effect of pregnancy on placental and of breastfeeding on mammal gland drug transporters, as well as physicochemical properties, C:M and M:P ratios of individual ARVs by drug class. Finally, we discussed the major safety issues of fetal and infant exposure to maternal ARVs.
Conclusions: Available pharmacological data provide evidence that physiological changes during pregnancy affect maternal, and consequently, fetal ARV exposure. Limited available data suggest that the expression of drug transporters may vary throughout pregnancy and breastfeeding thereby possibly impacting the amount of ARV crossing the placenta and secreted into the breast milk. The drug transporter’s role in the fetal/child exposure to maternal ARVs needs to be better understood. Our analysis underscores the need for more pharmacological studies with innovative study design, sparse PK sampling, improved study data reporting and PK modelling in pregnant and breastfeeding women living with HIV to optimize their treatment choices and maternal and child health outcomes.
Keywords: HIV, women, antiretroviral drugs, pharmacology, pregnancy, placental transfer, breastfeeding.
[1] 
 Joint United Nations Programme on HIV and AIDS (UNAIDS).
progress towards the 90-90-90 targets. Global AIDS update 2017.
2017. Available from:  http://www.unaids.org/sites/ default/files/media_asset/Global_AIDS_update_2017_en.pdf
[2] 
World Health Organization (WHO). Global guidance in criteria and process for validation: elimination of mother-to-child transmission of HIV and syphillis 2017.Available from:. http://apps. who.int/iris/bitstream/handle/10665/259517/9789241513272-eng.pdf?sequence=1
[3] 
Taylor M, Newman L, Ishikawa N, et al. Elimination of mother-to-child transmission of HIV and Syphilis (EMTCT): Process, progress, and program integration. PLoS Med  2017; 14: e1002329.
[4] 
Townsend CL, Byrne L, Cortina-Borja M, et al. Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000-2011. Aids  28: 1049-57.
[5] 
Centers for Disease Control and Prevention (CDC). Enhanced
perinatal surveillance – 15 areas, 2005-2008. HIV Surveillance
Supplemental Report. 2011; Volume 16, Number 2. Available
from:  https://www.cdc.gov/hiv/library/reports/hiv-surveillance-archive.html#supplemental-archive
[6] 
Joint United Nations Programme on HIV and AIDS (UNAIDS). UNAIDS data 2018. Available from:. http://www.unaids.org/sites/ default/files/media_asset/unaids-data-2018_en.pdf
[7] 
Knettel BA, Cichowitz C, Ngocho JS, et al. Retention in HIV Care During Pregnancy and the Postpartum Period in the Option B+ Era: Systematic Review and Meta-Analysis of Studies in Africa. J Acquir Immune Defic Syndr  2018; 77: 427-38.
[8] 
 United Nations Children’s Fund (UNICEF). For Every Child, End AIDS: Seventh Stocktaking Report. 2016.Available from:. https://www.unicef.org/publications/files/Children_and_AIDS_Seventh_Stocktaking_Report_2016_EN.pdf.pdf
[9] 
 World Health Organization (WHO). Prevention of mother-to-child transmission of HIV: selection and use of nevirapine  Technical
notes. WHO/HIV_AIDS/2001.03. 2001. Available from: . http:// www.who.int/hiv/pub/mtct/en/who_hiv_aids_2001.03.pdf?ua=1
[10] 
 World Health Organization (WHO).  Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants World Health Organization: Geneva 2010. Available from:. http://apps.who.int/iris/bitstream/handle/10665/75236/9789241599818_eng.pdf?sequence=1
[11] 
 World Health Organization (WHO).  Consolidated guidelines on general HIV care and the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach World Health Organization: Geneva 2013. Available from: http://www.who.int/hiv/pub/guidelines/arv2013/en/
[12] 
Joint United Nations Programme on HIV and AIDS (UNAIDS),
United Nations Children’s Fund (UNICEF), World Health Organization
(WHO). Global AIDS Response Progress Reporting 2016.
2016. Available from: https://aidsreportingtool. unaids.org/static/docs/GARPR_Guidelines_2016_EN.pdf
[13] 
Idele P, Hayashi C, Porth T, Mamahit A, Mahy M. Prevention of Mother-to-Child Transmission of HIV and Paediatric HIV Care and Treatment Monitoring: From Measuring Process to Impact and Elimination of Mother-to-Child Transmission of HIV. AIDS Behav  2017; 21: 23-33.
[14] 
 World Health Organization (WHO). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: what’s new 2015.Available from: . http://www.who. int/hiv/pub/arv/policy-brief-arv-2015/en/
[15] 
 World Health Organization (WHO).  Consolidated guidelines onthe use of antiretroviral drugs for treating and preventing HIV infection Recommendations for a public health approach. World Health
Organization: Geneva 2016. Available from: http://apps. who.int/iris/bitstream/handle/10665/208825/9789241549684_eng.pdf?sequence=1
[16] 
 European AIDS Clinical Society (EACS). Guidelines Version 9.0,
October 2017 Available from:  http://www.eacsociety.org/ files/guidelines_9.0-english.pdf
[17] 
 United States Department of Health and Human Services (DHHS)
Panel on Treatment of Pregnant Women with HIV Infection and
Prevention of Perinatal Transmission. Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States 2017.
[18] 
World Health Organization (WHO). Update on antiretroviral regimensfor treating and preventing HIV infection and update on early
infant diagnosis of HIV World Health Organization: Geneva 2018.
Available from: http://apps.who.int/ iris/bitstream/handle/ 10665/273129/WHO-CDS-HIV-18.19-eng.pdf?ua=1
[19] 
European AIDS Clinical Society (EACS). Guidelines Version 9.1,
October 2018 2018. Available from: http://www.eacsociety. org/files/2018_guidelines-9.1-english.pdf
[20] 
Moodley J, Moodley D, Pillay K, et al. Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J Infect Dis  1998; 178: 1327-33.
[21] 
Marzolini C, Decosterd L, Winterfeld U, et al. Free and total plasma concentrations of elvitegravir/cobicistat during pregnancy and postpartum: A case report. Br J Clin Pharmacol  2017; 83: 2835-8.
[22] 
Schalkwijk S, Colbers A, Konopnicki D, Greupink R, Russel FG, Burger D. network P. First reported use of elvitegravir and cobicistat during pregnancy. AIDS  2016; 30: 807-8.
[23] 
McCormack SA, Best BM. Protecting the fetus against HIV infection: A systematic review of placental transfer of antiretrovirals. Clin Pharmacokinet  2014; 53: 989-1004.
[24] 
Else LJ, Taylor S, Back DJ, Khoo SH. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid). Antivir Ther  2011; 16: 1139-47.
[25] 
Koren G, Pariente G. Pregnancy-associated changes in pharmacokinetics and their clinical implications. Pharm Res  2018; 35: 61.
[26] 
Pariente G, Leibson T, Carls A, Adams-Webber T, Ito S, Koren G. Pregnancy-Associated Changes in Pharmacokinetics: A Systematic Review. PLoS Med  2016; 13: e1002160.
[27] 
Aweeka FT, Hu C, Huang L, et al. Alteration in cytochrome P450 3A4 activity as measured by a urine cortisol assay in HIV-1-infected pregnant women and relationship to antiretroviral pharmacokinetics. HIV Med  2015; 16: 176-83.
[28] 
Jeong H, Choi S, Song JW, Chen H, Fischer JH. Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination. Xenobiotica  2008; 38: 62-75.
[29] 
Acosta EP, Gerber JG. Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Res Hum Retroviruses  2002; 18: 825-34.
[30] 
Burger DM. The role of therapeutic drug monitoring in pediatric HIV/AIDS. Ther Drug Monit  2010; 32: 269-72.
[31] 
Pretorius E, Klinker H, Rosenkranz B. The role of therapeutic drug monitoring in the management of patients with human immunodeficiency virus infection. Ther Drug Monit  2011; 33: 265-74.
[32] 
Punyawudho B, Singkham N, Thammajaruk N, et al. Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients. Expert Rev Clin Pharmacol  2016; 9: 1583-95.
[33] 
Gilbert EM, Darin KM, Scarsi KK, McLaughlin MM. Antiretroviral Pharmacokinetics in Pregnant Women. Pharmacotherapy  2015; 35: 838-55.
[34] 
Momper JD, Best B, Wang J, et al. IMPAACT P1026s Protocol  Team. Tenofovir alafenamide pharmacokinetics with and without
cobicistat in pregnancy [THAB0302]. 2018. 10th IAS Conference
on HIV Science (IAS 2018). Available from:. http://programme.aids
2018.org/Abstract/Abstract/5960
[35] 
Akanbi MO, Scarsi KK, Taiwo B, Murphy RL. Combination nucleoside/nucleotide reverse transcriptase inhibitors for treatment of HIV infection. Expert Opin Pharmacother  2012; 13: 65-79.
[36] 
Stek AM, Best BM, Luo W, et al. Effect of pregnancy on emtricitabine pharmacokinetics. HIV Med  2012; 13: 226-35.
[37] 
Colbers AP, Hawkins DA, Gingelmaier A, et al. network P. The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women. AIDS  2013; 27: 739-48.
[38] 
Best BM, Mirochnick M, Capparelli EV, et al. Impact of pregnancy on abacavir pharmacokinetics. AIDS  2006; 20: 553-60.
[39] 
Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): A randomised, double-blind, placebo-controlled, non-inferiority trial. Lancet  2014; 383: 1474-82.
[40] 
Boffito M, Lamorde M, Watkins M, Pozniak A. Antiretroviral dose optimization: the future of efavirenz 400 mg dosing. Curr Opin HIV AIDS  2017; 12: 339-42.
[41] 
Cressey TR, Stek A, Capparelli E, et al. Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum. J Acquir Immune Defic Syndr  2012; 59: 245-52.
[42] 
Schalkwijk S, Colbers A, Best B, et al. Pharmacokinetics of
Efavirenz 600 mg QD during Pregnancy and Postpartum [Abstract
433]. 2016. 2016 Conference on Retroviruses and Opportunistic Infections
(CROI). Boston, Massachusetts. Available from: http://www.croiconference.org/sites/default/files/posters-2016/433.pdf
[43] 
Dooley KE, Denti P, Martinson N, et al. Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection. J Infect Dis  2015; 211: 197-205.
[44] 
Olagunju A, Bolaji O, Amara A, et al. Pharmacogenetics of pregnancy-induced changes in efavirenz pharmacokinetics. Clin Pharmacol Ther  2015; 97: 298-306.
[45] 
Lamorde M, Wang X, Neary M, et al. Pharmacokinetics, pharmacodynamics
and pharmacogenomics of efavirenz 400mg once-daily
during pregnancy and postpartum [TUPDB0203LB]. 2017. 9th IAS
Conference on HIV Science (IAS 2017). Available from: http://programme.ias2017.org/Abstract/Abstract/5612
[46] 
Schalkwijk S, Ter Heine R, Colbers AC, et al. A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400 mg in Pregnant Women . Clin
Pharmacokinet, 2018. Available from:. https://www. ncbi.nlm.nih.gov/pubmed/29520730
[47] 
Mulligan N, Schalkwijk S, Best BM, et al. Etravirine Pharmacokinetics in HIV-Infected Pregnant Women. Front Pharmacol  2016; 7: 239.
[48] 
Olagunju A, Bolaji O, Neary M, Back D, Khoo S, Owen A. Pregnancy affects nevirapine pharmacokinetics: evidence from a CYP2B6 genotype-guided observational study. Pharmacogenet Genomics  2016; 26: 381-9.
[49] 
Tran AH, Best BM, Stek A, et al. Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women. J Acquir Immune Defic Syndr  2016; 72: 289-96.
[50] 
Osiyemi O, Yasin S, Zorrilla C, et al. Pharmacokinetics, Antiviral Activity, and Safety of Rilpivirine in Pregnant Women with HIV-1 Infection: Results of a Phase 3b, Multicenter, Open-Label Study. Infect Dis Ther  2018; 7: 147-59.
[51] 
Schalkwijk S, Colbers A, Konopnicki D, et al. Pharmacokinetics of newly developed antiretroviral agents in H. I. V. infected pregnant women Network. Lowered Rilpivirine Exposure During the Third Trimester of Pregnancy in Human Immunodeficiency Virus Type 1-Infected Women. Clin Infect Dis  2017; 65: 1335-41.
[52] 
Ramgopal M, Osiyemi O, Zorrilla C, et al. Pharmacokinetics of Total and Unbound Etravirine in HIV-1-Infected Pregnant Women. J Acquir Immune Defic Syndr  2016; 73: 268-74.
[53] 
Capparelli EV, Aweeka F, Hitti J, et al. Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics. HIV Med  2008; 9: 214-20.
[54] 
Lamorde M, Byakika-Kibwika P, Okaba-Kayom V, et al. Suboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1-seropositive Ugandan women. J Acquir Immune Defic Syndr  2010; 55: 345-50.
[55] 
Barry M, Gibbons S, Back D, Mulcahy F. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet  1997; 32: 194-209.
[56] 
Momper JD, Best B, Wang J, et al. Pharmacokinetics of darunavir
boosted with cobicistat during pregnancy and postpartum
[WEPEB118]. 2018. 10th IAS Conference on HIV Science (IAS
2018). Available from: http://programme.aids2018.org/Abstract/ Abstract/6026
[57] 
Molto J, Curran A, Miranda C, et al. Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients. J Antimicrob Chemother  2018; 73: 732-7.
[58] 
Boffito M, Back DJ, Blaschke TF, et al. Protein binding in antiretroviral therapies. AIDS Res Hum Retroviruses  2003; 19: 825-35.
[59] 
Kreitchmann R, Best BM, Wang J, et al. Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy. J Acquir Immune Defic Syndr  2013; 63: 59-66.
[60] 
Mirochnick M, Best BM, Stek AM, et al. Team IsS. Atazanavir pharmacokinetics with and without tenofovir during pregnancy. J Acquir Immune Defic Syndr  2011; 56: 412-9.
[61] 
Taburet AM, Piketty C, Chazallon C, et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother  2004; 48: 2091-6.
[62] 
Le MP, Mandelbrot L, Descamps D, et al. Pharmacokinetics, safety and efficacy of ritonavir-boosted atazanavir (300/100 mg once daily) in HIV-1-infected pregnant women. Antivir Ther  2015; 20: 507-13.
[63] 
Colbers A, Hawkins D, Hidalgo-Tenorio C, et al. network P. Atazanavir exposure is effective during pregnancy regardless of tenofovir use. Antivir Ther  2015; 20: 57-64.
[64] 
Ripamonti D, Cattaneo D, Maggiolo F, et al. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. AIDS  2007; 21: 2409-15.
[65] 
Foca E, Calcagno A, Bonito A, et al. Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients. J Antimicrob Chemother  2017; 72: 3163-6.
[66] 
Colbers A, Molto J, Ivanovic J, et al. Pharmacokinetics of total and unbound darunavir in HIV-1-infected pregnant women. J Antimicrob Chemother  2015; 70: 534-42.
[67] 
Lambert J, Jackson V, Else L, et al. Darunavir pharmacokinetics throughout pregnancy and postpartum. J Int AIDS Soc  2014; 17: 19485.
[68] 
Zorrilla CD, Wright R, Osiyemi OO, et al. Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily. HIV Med  2014; 15: 50-6.
[69] 
Crauwels HM, Kakuda TN, Ryan B, et al. Pharmacokinetics of once-daily darunavir/ritonavir in HIV-1-infected pregnant women. HIV Med  2016; 17: 643-52.
[70] 
Stek A, Best BM, Wang J, et al. Pharmacokinetics of Once Versus Twice Daily Darunavir in Pregnant HIV-Infected Women. J Acquir Immune Defic Syndr  2015; 70: 33-41.
[71] 
Stek A, Best B, Caparelli E, et al. Pharmacokinetics of Increased
Dose Darunavir During Late Pregnancy and Postpartum [Abstract
775]. 2016. 2016 Conference on Retroviruses and Opportunistic Infections
(CROI). Boston, Massachusetts. Available from:  http:
//www.croiconference.org/sites/default/files/posters-2016/775.pdf
[72] 
Else LJ, Douglas M, Dickinson L, Back DJ, Khoo SH, Taylor GP. Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations. Antimicrob Agents Chemother  2012; 56: 816-24.
[73] 
Lambert JS, Else LJ, Jackson V, et al. Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy. HIV Med  2011; 12: 166-73.
[74] 
Santini-Oliveira M, Estrela Rde C, Veloso VG, et al. Randomized clinical trial comparing the pharmacokinetics of standard- and increased-dosage lopinavir-ritonavir coformulation tablets in HIV-positive pregnant women. Antimicrob Agents Chemother  2014; 58: 2884-93.
[75] 
Sha BE, Tierney C, Sun X, et al.  Pharmacokinetic Exposure and
Virologic Response in Hiv-1 Infected Pregnant Women Treated
with Lopinavir/Ritonavir: Aids Clinical Trials Group Protocol
A5153s: A Substudy to A5150. Jacobs J AIDS HIV 2015; (1)3
[76] 
Stek AM, Mirochnick M, Capparelli E, et al. Reduced lopinavir exposure during pregnancy. AIDS  2006; 20: 1931-9.
[77] 
Mirochnick M, Best BM, Stek AM, et al. Team PsS. Lopinavir exposure with an increased dose during pregnancy. J Acquir Immune Defic Syndr  2008; 49: 485-91.
[78] 
Best BM, Stek AM, Mirochnick M, et al. Lopinavir tablet pharmacokinetics with an increased dose during pregnancy. J Acquir Immune Defic Syndr  2010; 54: 381-8.
[79] 
Fayet-Mello A, Buclin T, Guignard N, et al. Swiss HIVCS, Mother, Child HIVCS. Free and total plasma levels of lopinavir during pregnancy, at delivery and postpartum: implications for dosage adjustments in pregnant women. Antivir Ther  2013; 18: 171-82.
[80] 
Patterson KB, Dumond JB, Prince HA, et al. Protein binding of lopinavir and ritonavir during 4 phases of pregnancy: implications for treatment guidelines. J Acquir Immune Defic Syndr  2013; 63: 51-8.
[81] 
Mulligan N, Best BM, Wang J, et al. Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV. AIDS  2018; 32: 729-37.
[82] 
Bollen P, Colbers A, Schalkwijk S, Konopnicki D, Weizsäcker K, Hidalgo Tenorio C. A comparison of the pharmacokinetics of dolutegravir during pregnancy and postpartum A comparison of the pharmacokinetics of dolutegravir during pregnancy and postpartum 2017. International Workshop on Clinical Pharmacology of
Antiviral Therapy. Available from: . http://www.natap.org/ 2017/Pharm/Pharm_34.htm
[83] 
Orrell C, Kintu K, Coombs J, et al. DolPHIN-1 Study Group Dol-
PHIN-1: Randomised controlled trial of dolutegravir (DTG)- versus
efavirenz (EFV)-based therapy in mothers initiating antiretroviral
treatment in late pregnancy [THAB0307LB]. 2018. 10th IAS
Conference on HIV Science (IAS 2018). Available from:. http://programme.aids2018.org/Abstract/Abstract/13144
[84] 
Blonk MI, Colbers AP, Hidalgo-Tenorio C, et al. Pharmacokinetics of Newly Developed Antiretroviral Agents in HIVIPWPN, Network P. Raltegravir in HIV-1-Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy. Clin Infect Dis  2015; 61: 809-16.
[85] 
Watts DH, Stek A, Best BM, et al. team Iss. Raltegravir pharmacokinetics during pregnancy. J Acquir Immune Defic Syndr  2014; 67: 375-81.
[86] 
Colbers A, Schalkwijk S, Konopnicki D, Rockstroh J, Burger D. Elvitegravir pharmacokinetics during Pregnancy and Postpartum. 2018 19th International Workshop on Clinical Pharmacology of Antiviral Therapy 2018.Baltimore, USA. 
[87] 
Momper JD, Best BM, Wang J, et al. Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV. AIDS  2018; 32: 2507-16.
[88] 
Colbers A, Best B, Schalkwijk S, et al. the IST. Maraviroc Pharmacokinetics in HIV-1-Infected Pregnant Women. Clin Infect Dis  2015; 61: 1582-9.
[89] 
Schalkwijk S, Colbers A, Konopnicki D, et al. network P. The pharmacokinetics of abacavir 600 mg once daily in HIV-1-positive pregnant women. AIDS  2016; 30: 1239-44.
[90] 
Crauwels HM, Osiyemi O, Zorrilla C, Bicer C, Brown K.  Pharmacokinetics
of Total and Unbound Darunavir in HIV-1–infected
Pregnant Women Receiving a Darunavir/Cobicistat-based Regimen
[Poster 36]. 2018. 2018 Conference on Retroviruses and Opportunistic
Infections (CROI). Boston, Massachusetts. Available from: http://www.natap.org/2018/CROI/HIV&Women2018DRVcPKPregnancyPoster_JUV-63244_FINAL.PDF
[91] 
Huppertz B. The anatomy of the normal placenta. J Clin Pathol  2008; 61: 1296-302.
[92] 
Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med  1994; 331: 1173-80.
[93] 
World Health Organization (WHO). Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants in resource-limited settings: towards universal access  Recommendations
for a public health approach. World Health Organization: Geneva
2006. Available from:. http://www.who.int/hiv/ pub/mtct/arv_guidelines_mtct.pdf?ua=1
[94] 
Marzolini C, Kim RB. Placental transfer of antiretroviral drugs. Clin Pharmacol Ther  2005; 78: 118-22.
[95] 
Meyer Zu Schwabedissen HE, Grube M, Heydrich B, et al. Expression, localization, and function of MRP5 (ABCC5), a transporter for cyclic nucleotides, in human placenta and cultured human trophoblasts: effects of gestational age and cellular differentiation. Am J Pathol  2005; 166: 39-48.
[96] 
Sato K, Sugawara J, Sato T, et al. Expression of organic anion transporting polypeptide E (OATP-E) in human placenta. Placenta  2003; 24: 144-8.
[97] 
Ugele B, St-Pierre MV, Pihusch M, Bahn A, Hantschmann P. Characterization and identification of steroid sulfate transporters of human placenta. Am J Physiol Endocrinol Metab  2003; 284: E390-8.
[98] 
Sata R, Ohtani H, Tsujimoto M, et al. Functional analysis of organic cation transporter 3 expressed in human placenta. J Pharmacol Exp Ther  2005; 315: 888-95.
[99] 
Govindarajan R, Bakken AH, Hudkins KL, et al. In situ hybridization and immunolocalization of concentrative and equilibrative nucleoside transporters in the human intestine, liver, kidneys, and placenta. Am J Physiol Regul Integr Comp Physiol  2007; 293: R1809-22.
[100] 
Staud F, Cerveny L, Ceckova M. Pharmacotherapy in pregnancy; effect of ABC and SLC transporters on drug transport across the placenta and fetal drug exposure. J Drug Target  2012; 20: 736-63.
[101] 
Tetro N, Moushaev S, Rubinchik-Stern M, Eyal S. The Placental Barrier: the Gate and the Fate in Drug Distribution. Pharm Res  2018; 35: 71.
[102] 
Lankas GR, Wise LD, Cartwright ME, Pippert T, Umbenhauer DR. Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. Reprod Toxicol  1998; 12: 457-63.
[103] 
Mathias AA, Hitti J, Unadkat JD. P-glycoprotein and breast cancer resistance protein expression in human placentae of various gestational ages. Am J Physiol Regul Integr Comp Physiol  2005; 289: R963-9.
[104] 
Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther  2004; 75: 13-33.
[105] 
Moss MD, Siccardi M, Marzolini C. Mechanisms of drug interactions
II: Transport proteins.Drug interactions in Infectious Diseases 2018; 49-85.
[106] 
van der Galien R, Ter Heine R, Greupink R, et al. Pharmacokinetics of HIV-Integrase Inhibitors During Pregnancy: Mechanisms, Clinical Implications and Knowledge Gaps. Clin Pharmacokinet  2019; 58: 309-23.
[107] 
Marzolini C, Mueller R, Li-Blatter X, Battegay M, Seelig A. The brain entry of HIV-1 protease inhibitors is facilitated when used in combination. Mol Pharm  2013; 10: 2340-9.
[108] 
 ChemAxon Ltd. Chemicalize. Last accessed: 23/07/2018. Available
from: https://chemicalize.com/
[109] 
Chappuy H, Treluyer JM, Jullien V, et al. Maternal-fetal transfer and amniotic fluid accumulation of nucleoside analogue reverse transcriptase inhibitors in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother  2004; 48: 4332-6.
[110] 
Fauchet F, Treluyer JM, Preta LH, et al. Population pharmacokinetics of abacavir in pregnant women. Antimicrob Agents Chemother  2014; 58: 6287-9.
[111] 
Hirt D, Urien S, Rey E, et al. Population pharmacokinetics of emtricitabine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Antimicrob Agents Chemother  2009; 53: 1067-73.
[112] 
Flynn PM, Mirochnick M, Shapiro DE, et al. Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants. Antimicrob Agents Chemother  2011; 55: 5914-22.
[113] 
Rimawi BH, Johnson E, Rajakumar A, et al. Pharmacokinetics and Placental Transfer of Elvitegravir, Dolutegravir, and Other Antiretrovirals during Pregnancy. Antimicrob Agents Chemother  2017; 61: e02213-6.
[114] 
Calcagno A, Trentini L, Marinaro L, et al. Transplacental passage of etravirine and maraviroc in a multidrug-experienced HIV-infected woman failing on darunavir-based HAART in late pregnancy. J Antimicrob Chemother  2013; 68: 1938-9.
[115] 
Yeh RF, Rezk NL, Kashuba AD, et al. Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women. Antimicrob Agents Chemother  2009; 53: 2367-74.
[116] 
Mandelbrot L, Peytavin G, Firtion G, Farinotti R. Maternal-fetal transfer and amniotic fluid accumulation of lamivudine in human immunodeficiency virus-infected pregnant women. Am J Obstet Gynecol  2001; 184: 153-8.
[117] 
Benaboud S, Treluyer JM, Urien S, et al. Pregnancy-related effects on lamivudine pharmacokinetics in a population study with 228 women. Antimicrob Agents Chemother  2012; 56: 776-82.
[118] 
Mirochnick M, Taha T, Kreitchmann R, et al. Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life. J Acquir Immune Defic Syndr  2014; 65: 33-41.
[119] 
Hirt D, Urien S, Ekouevi DK, et al. Anrs. Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109). Clin Pharmacol Ther  2009; 85: 182-9.
[120] 
Mirochnick M, Rodman JH, Robbins BL, et al. Pharmacokinetics of oral zidovudine administered during labour: A preliminary study. HIV Med  2007; 8: 451-6.
[121] 
Rodman JH, Flynn PM, Robbins B, et al. Systemic pharmacokinetics and cellular pharmacology of zidovudine in human immunodeficiency virus type 1-infected women and newborn infants. J Infect Dis  1999; 180: 1844-50.
[122] 
Watts DH, Brown ZA, Tartaglione T, et al. Pharmacokinetic disposition of zidovudine during pregnancy. J Infect Dis  1991; 163: 226-32.
[123] 
Fauchet F, Treluyer JM, Valade E, et al. Maternal and fetal zidovudine pharmacokinetics during pregnancy and labour: too high dose infused at labour? Br J Clin Pharmacol  2014; 78: 1387-96.
[124] 
Phuapradit W, Sirinavin S, Taneepanichskul S, et al. Maternal and umbilical cord serum zidovudine levels in human immunodeficiency virus infection. Aust N Z J Obstet Gynaecol  1998; 38: 288-92.
[125] 
Izurieta P, Kakuda TN, Feys C, Witek J. Safety and pharmacokinetics of etravirine in pregnant HIV-1-infected women. HIV Med  2011; 12: 257-8.
[126] 
Ivanovic J, Nicastri E, Anceschi MM, et al. Pregnancy, Newborn Clinical Outcome Group in HIVI. Transplacental transfer of antiretroviral drugs and newborn birth weight in HIV-infected pregnant women. Curr HIV Res  2009; 7: 620-5.
[127] 
Benaboud S, Ekouevi DK, Urien S, et al. Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates. Antimicrob Agents Chemother  2011; 55: 331-7.
[128] 
Taylor GP, Lyall EG, Back D, Ward C, Tudor-Williams G. Pharmacological implications of lengthened in-utero exposure to nevirapine. Lancet  2000; 355: 2134-5.
[129] 
Musoke P, Guay LA, Bagenda D, et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS  1999; 13: 479-86.
[130] 
Marzolini C, Rudin C, Decosterd LA, et al. Swiss Mother + Child HIVCS. Transplacental passage of protease inhibitors at delivery. AIDS  2002; 16: 889-93.
[131] 
Mirochnick M, Fenton T, Gagnier P, et al. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis  1998; 178: 368-74.
[132] 
Gingelmaier A, Kurowski M, Kastner R, et al. Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery. AIDS  2006; 20: 1737-43.
[133] 
Conradie F, Zorrilla C, Josipovic D, et al. Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women. HIV Med  2011; 12: 570-9.
[134] 
Lechelt M, Lyons F, Clarke A, Magaya V, Issa R, de Ruiter A. Human placental transfer of atazanavir: A case report. AIDS  2006; 20: 307.
[135] 
Ivanovic J, Bellagamba R, Nicastri E, et al. Use of darunavir/ritonavir once daily in treatment-naive pregnant woman: pharmacokinetics, compartmental exposure, efficacy and safety. AIDS  2010; 24: 1083-4.
[136] 
Ripamonti D, Cattaneo D, Cortinovis M, Maggiolo F, Suter F. Transplacental passage of ritonavir-boosted darunavir in two pregnant women. Int J STD AIDS  2009; 20: 215-6.
[137] 
Pinnetti C, Tamburrini E, Ragazzoni E, De Luca A, Navarra P. Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1. Antivir Ther  2010; 15: 127-9.
[138] 
Pinnetti C, Baroncelli S, Villani P, et al. Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy. J Antimicrob Chemother  2010; 65: 2050-2.
[139] 
Croci L, Trezzi M, Allegri MP, et al. Pharmacokinetic and safety of raltegravir in pregnancy. Eur J Clin Pharmacol  2012; 68: 1231-2.
[140] 
Lewis JM, Railton E, Riordan A, Khoo S, Chaponda M. Early experience of dolutegravir pharmacokinetics in pregnancy: high maternal levels and significant foetal exposure with twice-daily dosing. AIDS  2016; 30: 1313-5.
[141] 
Shapiro RL, Rossi S, Ogwu A, et al. Therapeutic levels of lopinavir in late pregnancy and abacavir passage into breast milk in the Mma Bana Study, Botswana. Antivir Ther  2013; 18: 585-90.
[142] 
Waitt C, Olagunju A, Nakalema S, et al. Plasma and breast milk pharmacokinetics of emtricitabine, tenofovir and lamivudine using dried blood and breast milk spots in nursing African mother-infant pairs. J Antimicrob Chemother  2018; 73: 1013-9.
[143] 
Mugwanya KK, Hendrix CW, Mugo NR, et al. Pre-exposure Prophylaxis Use by Breastfeeding HIV-Uninfected Women: A Prospective Short-Term Study of Antiretroviral Excretion in Breast Milk and Infant Absorption. PLoS Med  2016; 13: e1002132.
[144] 
Corbett AH, Kayira D, White NR, et al. Antiretroviral pharmacokinetics in mothers and breastfeeding infants from 6 to 24 weeks post-partum: results of the BAN Study. Antivir Ther  2014; 19: 587-95.
[145] 
Giuliano M, Guidotti G, Andreotti M, et al. Triple antiretroviral prophylaxis administered during pregnancy and after delivery significantly reduces breast milk viral load: A study within the Drug Resource Enhancement Against AIDS and Malnutrition Program. J Acquir Immune Defic Syndr  2007; 44: 286-91.
[146] 
Palombi L, Pirillo MF, Andreotti M, et al. Antiretroviral prophylaxis for breastfeeding transmission in Malawi: drug concentrations, virological efficacy and safety. Antivir Ther  2012; 17: 1511-9.
[147] 
Palombi L, Pirillo MF, Marchei E, et al. Concentrations of tenofovir, lamivudine and efavirenz in mothers and children enrolled under the Option B-Plus approach in Malawi. J Antimicrob Chemother  2016; 71: 1027-30.
[148] 
Mirochnick M, Thomas T, Capparelli E, et al. Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. Antimicrob Agents Chemother  2009; 53: 1170-6.
[149] 
Shapiro RL, Holland DT, Capparelli E, et al. Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment. J Infect Dis  2005; 192: 720-7.
[150] 
Schneider S, Peltier A, Gras A, et al. Efavirenz in human breast milk, mothers’, and newborns’ plasma. J Acquir Immune Defic Syndr  2008; 48: 450-4.
[151] 
Spencer LY, Liu S, Wang C, Neely M, Louie S. Intensive Etravirine
PK and HIV-1 Viral Load in Breast Milk and Plasma in
HIV+ Women Receiving HAART [Abstract 891]. 2014. 2014 Conference
on Retroviruses and Opportunistic Infections (CROI). Boston,
Massachusetts. Available http://www.croiconference.org/ sites/default/files/posters/891.pdf
[152] 
Colebunders R, Hodossy B, Burger D, et al. The effect of highly active antiretroviral treatment on viral load and antiretroviral drug levels in breast milk. AIDS  2005; 19: 1912-5.
[153] 
Kobbe R, Schalkwijk S, Dunay G, et al. Dolutegravir in breast milk and maternal and infant plasma during breastfeeding. AIDS  2016; 30: 2731-3.
[154] 
Annaert P, Ye ZW, Stieger B, Augustijns P. Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. Xenobiotica  2010; 40: 163-76.
[155] 
Begley R, Das M, Zhong L, Ling J, Kearney BP, Custodio JM. Pharmacokinetics of Tenofovir Alafenamide When Coadministered With Other HIV Antiretrovirals. J Acquir Immune Defic Syndr  2018; 78: 465-72.
[156] 
Cano-Soldado P, Lorrayoz IM, Molina-Arcas M, et al. Interaction of nucleoside inhibitors of HIV-1 reverse transcriptase with the concentrative nucleoside transporter-1 (SLC28A1). Antivir Ther  2004; 9: 993-1002.
[157] 
Ceckova M, Reznicek J, Ptackova Z, et al. Role of ABC and Solute Carrier Transporters in the Placental Transport of Lamivudine. Antimicrob Agents Chemother  2016; 60: 5563-72.
[158] 
Cihlar T, Ho ES, Lin DC, Mulato AS. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids  2001; 20: 641-8.
[159] 
Custodio JM, Wang H, Hao J, et al. Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin. J Clin Pharmacol  2014; 54: 649-56.
[160] 
Hoque MT, Kis O, De Rosa MF, Bendayan R. Raltegravir permeability across blood-tissue barriers and the potential role of drug efflux transporters. Antimicrob Agents Chemother  2015; 59: 2572-82.
[161] 
Hyland R, Dickins M, Collins C, Jones H, Jones B. Maraviroc: in vitro assessment of drug-drug interaction potential. Br J Clin Pharmacol  2008; 66: 498-507.
[162] 
Kis O, Zastre JA, Ramaswamy M, Bendayan R. pH dependence of organic anion-transporting polypeptide 2B1 in Caco-2 cells: potential role in antiretroviral drug oral bioavailability and drug-drug interactions. J Pharmacol Exp Ther  2010; 334: 1009-22.
[163] 
Lepist EI, Zhang X, Hao J, et al. Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat. Kidney Int  2014; 86: 350-7.
[164] 
Moss DM, Siccardi M, Murphy M, et al. Divalent metals and pH alter raltegravir disposition in vitro. Antimicrob Agents Chemother  2012; 56: 3020-6.
[165] 
Muller F, Konig J, Hoier E, Mandery K, Fromm MF. Role of organic cation transporter OCT2 and multidrug and toxin extrusion proteins MATE1 and MATE2-K for transport and drug interactions of the antiviral lamivudine. Biochem Pharmacol  2013; 86: 808-15.
[166] 
Reese MJ, Savina PM, Generaux GT, et al. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab Dispos  2013; 41: 353-61.
[167] 
Reznicek J, Ceckova M, Cerveny L, Muller F, Staud F. Emtricitabine is a substrate of MATE1 but not of OCT1, OCT2, P-gp, BCRP or MRP2 transporters. Xenobiotica  2017; 47: 77-85.
[168] 
Shaik N, Giri N, Pan G, Elmquist WF. P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution. Drug Metab Dispos  2007; 35: 2076-85.
[169] 
Takeda M, Khamdang S, Narikawa S, et al. Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther  2002; 300: 918-24.
[170] 
Wang X, Furukawa T, Nitanda T, et al. Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Mol Pharmacol  2003; 63: 65-72.
[171] 
Weiss J, Rose J, Storch CH, et al. Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrob Chemother  2007; 59: 238-45.
[172] 
Weiss J, Theile D, Ketabi-Kiyanvash N, Lindenmaier H, Haefeli WE. Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors. Drug Metab Dispos  2007; 35: 340-4.
[173] 
Yao SY, Ng AM, Sundaram M, Cass CE, Baldwin SA, Young JD. Transport of antiviral 3′-deoxy-nucleoside drugs by recombinant human and rat equilibrative, nitrobenzylthioinosine (NBMPR)-insensitive (ENT2) nucleoside transporter proteins produced in Xenopus oocytes. Mol Membr Biol  2001; 18: 161-7.
[174] 
Ye ZW, Camus S, Augustijns P, Annaert P. Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes. Biopharm Drug Dispos  2010; 31: 178-88.
[175] 
Zembruski NC, Haefeli WE, Weiss J. Interaction potential of etravirine with drug transporters assessed in vitro. Antimicrob Agents Chemother  2011; 55: 1282-4.
[176] 
Bailey H, Zash R, Rasi V, Thorne C. HIV treatment in pregnancy. Lancet HIV  2018; 5: e457-67.
[177] 
Sibiude J, Warszawski J, Tubiana R, et al. Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost? Clin Infect Dis  2012; 54: 1348-60.
[178] 
Powis KM, Kitch D, Ogwu A, et al. Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy. J Infect Dis  2011; 204: 506-14.
[179] 
Ravizza M, Martinelli P, Bucceri A, et al. Italian Group on Surveillance on Antiretroviral Treatment in P. Treatment with protease inhibitors and coinfection with hepatitis C virus are independent predictors of preterm delivery in HIV-infected pregnant women. J Infect Dis  2007; 195: 913-4.
[180] 
Fiore S, Ferrazzi E, Newell ML, Trabattoni D, Clerici M. Protease inhibitor-associated increased risk of preterm delivery is an immunological complication of therapy. J Infect Dis  2007; 195: 914-6.
[181] 
Fowler MG, Qin M, Fiscus SA, et al. Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention. N Engl J Med  2016; 375: 1726-37.
[182] 
Jao J, Abrams EJ, Phillips T, Petro G, Zerbe A, Myer L. In utero tenofovir exposure is not associated with fetal long bone growth. Clin Infect Dis  2016; 62: 1604-9.
[183] 
Siberry GK, Jacobson DL, Kalkwarf HJ, et al. Lower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate During Pregnancy. Clin Infect Dis  2015; 61: 996-1003.
[184] 
Vigano A, Mora S, Giacomet V, et al. In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers. Antivir Ther  2011; 16: 1259-66.
[185] 
Denneman L, Cohen S, Godfried MH, et al. In-utero exposure to tenofovir is associated with impaired fetal and infant growth: need for follow-up studies in combination antiretroviral therapy/HIV-exposed infants. AIDS  2016; 30: 2135-7.
[186] 
Liotta G, Floridia M, Andreotti M, et al. Growth indices in breastfed infants pre and postnatally exposed to tenofovir compared with tenofovir-unexposed infants. AIDS  2016; 30: 525-7.
[187] 
Ransom CE, Huo Y, Patel K, et al. Group PTotIMPAACT. Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy. J Acquir Immune Defic Syndr  2013; 64: 374-81.
[188] 
Williams PL, Hazra R, Van Dyke RB, et al. Antiretroviral exposure during pregnancy and adverse outcomes in HIV-exposed uninfected infants and children using a trigger-based design. AIDS  2016; 30: 133-44.
[189] 
Kourtis AP, Wiener J, Wang L, et al. Tenofovir disoproxil fumarate use during pregnancy and infant bone health: the Tenofovir in Pregnancy Pilot Study. Pediatr Infect Dis J 2018.
[190] 
Bristol-Myers Squibb Pharma Company.  SUSTIVA package insert 2005.Available from: . https://www.accessdata.fda.gov/ drugsatfda_docs/label/2005/020972s026,021360s013lbl.pdf
[191] 
Ford N, Mofenson L, Shubber Z, et al. Safety of efavirenz in the first trimester of pregnancy: An updated systematic review and meta-analysis. AIDS  2014; 28(Suppl. 2): S123-31.
[192] 
Zash R, Jacobson DL, Diseko M, et al. Comparative Safety of Antiretroviral Treatment Regimens in Pregnancy. JAMA Pediatr  2017; 171: e172222.
[193] 
 Antiretroviral Pregnancy Registry. Last accessed: Available from: http://www.apregistry.com/
[194] 
Zash R, Makhema J, Shapiro RL. Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception. N Engl J Med  2018; 379: 979-81.
[195] 
Shi L, Chia SE. A review of studies on maternal occupational exposures and birth defects, and the limitations associated with these studies. Occup Med (Lond)  2001; 51: 230-44.
[196] 
Hofer CB, Keiser O, Zwahlen M, et al. In Utero Exposure to Antiretroviral Drugs: Effect on Birth Weight and Growth Among HIV-exposed Uninfected Children in Brazil. Pediatr Infect Dis J  2016; 35: 71-7.
[197] 
Suchard MS, Mayne E, Green VA, et al. FOXP3 expression is upregulated in CD4T cells in progressive HIV-1 infection and is a marker of disease severity. PLoS One  2010; 5: e11762.
[198] 
Rasmussen SA, Barfield W, Honein MA. Protecting Mothers and Babies - A Delicate Balancing Act. N Engl J Med  2018; 379(10): 907-9.
[199] 
Brocklehurst P, French R. The association between maternal HIV infection and perinatal outcome: A systematic review of the literature and meta-analysis. Br J Obstet Gynaecol  1998; 105: 836-48.
[200] 
Wedi CO, Kirtley S, Hopewell S, Corrigan R, Kennedy SH, Hemelaar J. Perinatal outcomes associated with maternal HIV infection: A systematic review and meta-analysis. Lancet HIV  2016; 3: e33-48.
[201] 
Ito S, Alcorn J. Xenobiotic transporter expression and function in the human mammary gland. Adv Drug Deliv Rev  2003; 55: 653-65.
[202] 
Alcorn J, Lu X, Moscow JA, McNamara PJ. Transporter gene expression in lactating and nonlactating human mammary epithelial cells using real-time reverse transcription-polymerase chain reaction. J Pharmacol Exp Ther  2002; 303: 487-96.
[203] 
Jonker JW, Merino G, Musters S, et al. The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat Med  2005; 11: 127-9.
[204] 
Vlaming ML, Lagas JS, Schinkel AH. Physiological and pharmacological roles of ABCG2 (BCRP): recent findings in Abcg2 knockout mice. Adv Drug Deliv Rev  2009; 61: 14-25.
[205] 
Gilchrist SE, Alcorn J. Lactation stage-dependent expression of transporters in rat whole mammary gland and primary mammary epithelial organoids. Fundam Clin Pharmacol  2010; 24: 205-14.
[206] 
McNamara PJ, Abbassi M. Neonatal exposure to drugs in breast milk. Pharm Res  2004; 21: 555-66.
[207] 
 United States Department of Health and Human Services (DHHS), Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research
(CBER) https://www.fda.gov/downloads/ regulatoryinformation/guidances/ucm127505.pdf
[208] 
Olagunju A, Bolaji O, Amara A, et al. Breast milk pharmacokinetics of efavirenz and breastfed infants’ exposure in genetically defined subgroups of mother-infant pairs: An observational study. Clin Infect Dis  2015; 61: 453-63.
[209] 
Begg EJ, Duffull SB, Hackett LP, Ilett KF. Studying drugs in human milk: time to unify the approach. J Hum Lact  2002; 18: 323-32.
[210] 
Waitt CJ, Garner P, Bonnett LJ, Khoo SH, Else LJ. Is infant exposure to antiretroviral drugs during breastfeeding quantitatively important? A systematic review and meta-analysis of pharmacokinetic studies. J Antimicrob Chemother  2015; 70: 1928-41.
[211] 
Ito S. Drug therapy for breast-feeding women. N Engl J Med  2000; 343: 118-26.
[212] 
Fogel J, Li Q, Taha TE, et al. Initiation of antiretroviral treatment in women after delivery can induce multiclass drug resistance in breastfeeding HIV-infected infants. Clin Infect Dis  2011; 52: 1069-76.
[213] 
United States Department of Health and Human Services (DHHS),
Food and Drug Administration (FDA), Center for Drug Evaluation
and Research (CDER), Center for Biologics Evaluation and Research
(CBER). Center for Biologics Evaluation and Research
(CBER). Pregnant Women Scientific and Ethical Considerations
for Inclusion in Clinical Trials. Guidance for Industry. Draft Guidance.
2018. Available from: https://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM603873.pdf
[214] 
Colbers A, Schalkwijk S, Konopnicki D, et al. Timing of the postpartum curve in pharmackinetc studies in pregnancy should not be too early 2016.17th edition of the International Workshop on
Clinical Pharmacology of HIV & Hepatitis Therapy. Washington
DC, USA Available from:. http://regist2.virology-education.com/ 2016/17HIVHEPPK/04_Colbers.pdf
[215] 
De Sousa Mendes M, Hirt D, Urien S, et al. Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women. Br J Clin Pharmacol  2015; 80: 1031-41.
[216] 
Colbers A, Greupink R, Litjens C, Burger D, Russel FG. Physiologically based modelling of darunavir/ritonavir pharmacokinetics during pregnancy. Clin Pharmacokinet  2016; 55: 381-96.
[217] 
Schalkwijk S, Buaben AO, Freriksen JJM, et al. Prediction of fetal darunavir exposure by integrating human ex-vivo placental transfer and physiologically based pharmacokinetic modeling. Clin Pharmacokinet  2018; 57: 705-16.
[218] 
Lyerly AD, Little MO, Faden R. The second wave: Toward responsible inclusion of pregnant women in research. Int J Fem Approaches Bioeth  2008; 1: 5-22.
[219] 
Sheffield JS, Siegel D, Mirochnick M, et al. Designing drug trials: considerations for pregnant women. Clin Infect Dis  2014; 59(Suppl. 7): S437-44.
Cite As
Current Pharmaceutical Design

Pharmacokinetics, Placental and Breast Milk Transfer of Antiretroviral Drugs in Pregnant and Lactating Women Living with HIV

Abstract
